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Results: Mean friction resistance (N) was significantly decreased with the new support
system (0.840.28 vs. 1.260.31, n18, p0.01). Any unfavorable phenomenon such
as device fracture was not observed during the support system use.
Conclusions: The new intervention support system could reduce friction resistance
during device insertion. Therefore, the system has potential ability to contribute to make
complex coronary intervention procedures such as those to heavily calcified lesions or
chronic total occlusions easier.
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Background: Introduction of drug-eluting stents (DES), which have been demonstrated
to cause less restenosis than bare-metal stents (BMS) in specific patient and lesion subsets,
has raised hopes of improving long-term vessel patency after chronic total occlusion
(CTO) recanalization. However, limited evidence of the benefit and safety of DES use in
CTO is available. We aim to analyze the short and long term outcomes of patients with
CTO treated with the latest generation drug eluting stent (DES) by pulling data from
NOBORI 2 and eNOBORI registries.
Methods: NOBORI2 and eNOBORI are two large, prospective, single-arm, multi-center,
registries that enrolled 3067 and 7750 patients respectively, out of which 97 and 302 had
treated CTO. All adverse events were adjudicated by an independent clinical event
committee in NOBORI 2, while adjudication in eNOBORI (including stent thrombosis)
is ongoing. The primary endpoint was Target Lesion Failure (TLF), a composite of
cardiac death (CD), target vessel related myocardial infarction (MI) and target lesion
revascularization (TLR).
Results: CTO patients were 60y old, 83% males, 50% with prior MI, 28% prior PCI
and 5% previous cardiac surgery. Multiple vessels were treated in 33% of patients
(2.201.43lesions per patient). The lesions were complex (82% B2/C type), ostial (17%),
calcified (43%), contained thrombus (2%) and 7% required bifurcation treatment. Pre- and
post-dilatation were performed in 86% and 34% of lesions respectively. At 1-month, there
were no deaths nor TLR, while there were 3 MI (1.2%) and one TVR (0.4%). The TLF
rate was 1.2%. In the cohort of patients followed at 3-year, 3 patients suffered a cardiac
death (3.1%), 1 had an MI (1.0%), 3 underwent TLR (3.1%) and TLF rate was 6.2%. A
total of 87% of the patients were angina free. No stent thrombosis occurred up to 3 years.
Conclusions: Treatment of CTO with Nobori DES showed favourable short- and
long-term outcomes. Low rates of procedural complications, short and long term adverse
events and the absence of stent thrombosis up to 3 years, despite the multiple overlapping
stents suggest that this stent is valuable treatment option for patients with CTO disease
considered as candidates for PCI.
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Background: To evaluate ischemia with FFR and LV function response to the
myocardium supplied by a CTO in pts with LV systolic dysfunction (LV EF 0.50).
Methods: Pts referred for angiogram for angina on optimal medical therapy and LVEF
0.50 underwent FFR evaluation of CTO (after partial recanalization with a small 1.5
mm balloon) and underwent PCI of CTO.
Results: Ten CTO and 10 matched non-CTO pts with severe stenosis 70% were
studied. Baseline characteristics were similar: age(60.9 	 8.9yrs), sex(males90%),
HTN(90%), diabetes (45%), hyperlipidemia(80%), CRI(30%), bypass surgery(25%), h/o
MI(50%) and Q waves on ECG(35%). LVEF at baseline was 35.710.6% in the CTO
and 42.37.9 in the non-CTO pts, (p 0.24). Pre-PCI FFR were 0.460.17 in the CTO
and 0.420.16 in the non-CTO groups (p 0.83) and; post-PCI FFR was similar
(0.880.09, CTO group and 0.900.05 non-CTO group, p0.57). At a mean f/u of 1.4
yrs, LV EF was significantly improved to 45.39.5% in the CTO group vs 35.710.6%
at baseline (p0.01), while there was a non-significant LV EF improvement in the
non-CTO group (45.49.8% vs 42.37.9%, p0.18) as shown in figure.
Conclusions: In pts with LV systolic dysfunction there is demonstrable ischemia
(FFR0.80) in the CTO territory, that is relieved after CTO PCI (FFR 0.80) with an
improvement in the LV systolic function.
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Background: The “hybrid approach” to chronic total occlusion (CTO) interventions
advocates early and frequent change of the utilized strategy to maximize efficiency.
Methods: We prospectively recorded detailed procedural information (strategy change
with corresponding procedural and fluoroscopy time and patient radiation exposure in 61
consecutive patients undergoing CTO intervention between July 2011 and May 2012.
Results: Fifty-five of 61 patients had successful CTO intervention with an overall
procedural success rate of 90.2%. Mean age was 65 7 years, all patients were men and
32% had prior coronary artery bypass graft surgery. The primary approach was retrograde
for 7 patients (11.5%) and antegrade for 54 patients (88.5%), of whom 21 patients (34.5%)
underwent retrograde intervention after failed antegrade approach (Table). Thirty-three
patients (54%) had no approach change, but 28/61 patients (46%) required 3.81.4
approach changes (range 2 -7) (Figure). The mean procedure time, fluoroscopy time,
radiation exposure and catheters and wires used are summarized in the Table.
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CTO target vessel
RCA (%) 57.4
LCx (%) 21.3
LAD (%) 18.0
LM/graft (%) 3.3
Prior failed attempt for CTO PCI (%) 10
Dual injection used (%) 69
Intervention Approach
Antegrade only (%) 54.1
Antegrade followed by retrograde (%) 34.5
Primary retrograde (%) 11.4
Retrograde crossing Technique (n16)
Reverse CART (%) 69
Retrograde true to true lumen (%) 25
Just marker (%) 6
Collateral used (27 patients)
Septal (%) 73
Epicardial (%) 27
Number of approach changes for all patients (n61) 2.81.7
No. of approach changes for those with switch (n28) 3.81.4
Procedure time to cross CTO lesion (min)* 60 53
Fluoroscopy time to cross CTO lesion (min)* 23 21
Radiation exposure to cross CTO lesion (Gray) 2.54.3
Total procedure time (min)* 153 77
Total fluoroscopy time (min)* 43 26
Total radiation exposure (Gray)* 4.6 2.1
Total contrast volume (ml)* 382 152
Number of wires used* 118
Number of microcatheters used* 2.5 1.4
Number of balloons used* 5.02.5
Number of stents used* 3.01.5
Conclusions: In the “hybrid approach” to CTO intervention, multiple changes in the
crossing approach are needed in approximately half the patients, with a high overall
procedural success rate.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES),
EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of patients with
chronic total occlusion (CTO).
Methods: A prospective analysis of 1576 patients with 1738 CTOs (396 SES, 526 PES,
219 ZES-R, 209 BES, 148 ECS, 240 EES) in six high volume Asian centers after
successful recanalization of CTO was performed. The study endpoints were 30 days and
12 and 36 months major adverse cardiac events (MACE) and target lesion revascular-
ization (TLR).
Results: See table for clinical results.
Conclusions: The use of drug-eluting stents in patients with CTO was safe with low
acute complication. Patients treated with 2nd generation DES such as ZES-R, BES and
EES showed lesser rate of restenosis compared with 1st generation drug-eluting stents.
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Background: To evaluate the long-term efficacy of Sirolimus (SES), Paclitaxel (PES),
Everolimus (EES) and Zotarolimus-eluting stent (ZES-R/ Endeavor Resolute) on the
outcome of patients with chronic total occlusions (CTO).
Methods: A total of 378 patients with 414 CTO lesions (male 72.8%, mean age 69.9 yrs,
LAD 49.5%, LCX 21.0%, RCA 26.6%, Others 2.9%) were treated with SES (102 patients
118 lesions, lesion length 36.112.9mm, stent length 41.715.6mm), PES (108 patients
114 lesions, 38.512.8mm, 43.919.5mm), EES (88 patients 94 lesions, 34.213.8mm,
40.114.8mm) and ZES-R (80 patients 88 lesions, 37.113.9mm, 42.317.3mm)
respectively. We conducted follow-up coronary angiogram and evaluated late loss in all
patients after successful implantation of SES, PES, EES and ZES-R (9, 12, 18, 24, 36
months respectively).
Results: See table for clinical results.
Conclusions: There is a different timing of late catch up phenomenon (late lumen loss)
of SES, PES, EES and ZES-R (SES: 12-18 months, PES: 9-12 months, EES: 12-18
months and ZES-R: 12-24 months) after successful implantation of SES, PES, EES and
ZES-R in patients with chronic total occlusion. Patients treated with SES, EES and ZES-R
showed lesser loss of minimum lumen diameter compared with PES.
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